This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Lonza plans to invest approximately CHF 500 million to upgrade the facility
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The new campus has been designed as an employee-centred experience and ecosystem zone
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)